Global Health Care Reports €112.6 Million Loss After Writing Down milon Investment
Key Facts
Global Health Care AG said on November 18 that its draft 2025 annual financial statements show a net loss of €112.6 million, compared with a loss of €2.7 million in the previous year. The statements have not yet been approved by the general meeting, according to the company disclosure published via EQS. The figure mainly reflects a substantial write-down of financial investments, led by the company's stake in milon Holding GmbH. The company said total impairment expenses on financial assets amounted to €110.2 million. The figure distinguishes the accounting loss recorded during the year from the liquidity position, which the company described as strained.
The company reduced the carrying value of its investment in milon from €120.45 million to €13.50 million in its 2025 statements, recording an impairment loss of €106.95 million. It said the previous valuation was based on revenue and earnings forecasts that came in far below expectations. Accordingly, the management board commissioned a new valuation of milon Holding under IDW S 1, dated October 31, 2026. The milon write-down accounts for most of the total €110.2 million in impairment expenses on financial assets. Those expenses also covered another investment and receivables and loans associated with the investments.
Other items included the EasyMotionSkin Tec GmbH investment, which the company wrote down to nominal value, as well as the full write-off of outstanding receivables and loans owed by it. The company included these items in total impairment expenses on financial assets recorded in its 2025 statements. It said explicitly, however, that the impairments and write-offs did not affect liquidity during the year. At the same time, it described its liquidity position as strained. The disclosure thus linked cash pressures to the existing liquidity position without attributing them to the effect of the write-offs in 2025.
The company's equity fell from €123.4 million to €10.7 million. With share capital of €3.1 million, the management board said there had been no loss of half the share capital and no overindebtedness. The assessment appears in a disclosure concerning draft annual financial statements that have not yet been approved by the general meeting. The decline in equity shows the scale of the loss and asset impairments' effect on the reported financial position. The available information in the disclosure gave no new liquidity figure, but described the position as strained.
On financing, the company said its 2024/2029 corporate bond had not reached its target size, with €1.05 million placed as of the disclosure date. It added that talks with external investors and measures to improve its capital structure were ongoing. These steps provide further context for the description of strained liquidity, while the company says the impairments themselves did not affect 2025 liquidity. The disclosure does not specify the bond's target size or when the talks are expected to conclude. It also gave no final outcome for the measures to improve the capital structure.
Among the options the management board will consider at the general meeting is offering stakes in milon Holding GmbH for sale, including through a capital measure, as part of addressing liquidity pressures. No decision on a sale has been made, the company said. The use of the stakes is constrained by about half of them being pledged as security for a financing arrangement. The discussion follows the reduction in the carrying value of the milon investment to €13.50 million, but does not mean the company has decided to exit. The general meeting will be an opportunity to discuss the option, not an advance announcement that a transaction will be completed.
On the operating side, milon industries GmbH expects net revenue of about €45.6 million and EBITDA of about €6.2 million for full-year 2026. These forecasts relate to milon industries, while the write-down concerns Global Health Care's investment in milon Holding GmbH. The company also stated that its shares are listed on the unofficial regulated market in Munich. The 2025 annual financial statements remain in draft form pending approval by the general meeting. The board has also yet to decide on the option of selling the stakes or related measures.